Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus

Christina Jiang, Susuana Adjei, Sueheidi Santiago, Jun Lu, Miguel Duran, Stephen Tyring, Christina Jiang, Susuana Adjei, Sueheidi Santiago, Jun Lu, Miguel Duran, Stephen Tyring

No abstract available

Keywords: dupilumab; immunobiologic; pemphigus foliaceus; pemphigus vulgaris.

Conflict of interest statement

Drs Tyring and Lu have worked on clinical trials with Regeneron, but this study was self-funded. Drs Jiang, Adjei, Santiago, and Duran have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Case 2 - pemphigus vulgaris of left hand. A, Baseline of left hand: eroded plaque on the left lateral third digit. B, Left hand after 20 weeks of dupilumab: clinical remission. C, Left hand after 63 weeks of dupilumab: maintenance of clinical remission
Fig 2
Fig 2
Case 2 - pemphigus vulgaris of forearms. A, Baseline of dorsal aspect of the right forearm: scaly brown plaques with eroded bullae. B, Baseline of dorsal aspect of the left forearm: scaly brown plaques with eroded bullae. C, Bilateral dorsal aspect of the forearms after 40 weeks of dupilumab: scaly brown plaques that are decreased in size from baseline images, no bullae or ulcerations.
Fig 3
Fig 3
Case 2 - pemphigus vulgaris of left breast. A, Baseline of left breast: brown plaque with eroded bullae. B, Left breast after 63 weeks of dupilumab: postinflammatory hyperpigmentation without bullae.

References

    1. Malik A.M., Tupchong S., Huang S., Are A., Hsu S., Motaparthi K. An updated review of pemphigus diseases. Medicina (Kaunas) 2021;57(10):1080. doi: 10.3390/medicina57101080.
    1. Melchionda V., Harman K.E. Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management. Clin Exp Dermatol. 2019;44(7):740–746. doi: 10.1111/ced.14041.
    1. DUPIXENT Prescribing Information.
    1. Saleh M., Reedy M., Torok H., Weaver J. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature. Dermatol Online J. 2021;27(4) doi: 10.5070/d3274053155.
    1. Abdat R., Waldman R.A., de Bedout V., et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83(1):46–52. doi: 10.1016/j.jaad.2020.01.089.
    1. Moore A.Y., Hurley K. Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris. JAAD Case Rep. 2023;31:16–18. doi: 10.1016/j.jdcr.2022.10.035.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit